

## Amendments to the Claims

This listing of the claims will replace all prior versions and listings of claims in the application.

1. (Currently amended) A method for transducing a gene into ~~non-immortalized~~ activated CD8+ T cells, wherein said method comprises the step of contacting a paramyxovirus vector carrying the gene with activated ~~non-immortalized~~ CD8+ T cells.

2. (Original) The method according to claim 1, wherein the paramyxovirus vector is a Sendai virus vector.

3-8. (Canceled)

9. (Previously presented) The method according to claim 1, wherein the activated T cells are antigen-activated T cells.

10. (Withdrawn) The method according to claim 9, wherein the antigen is an alloantigen.

11. (Currently amended) The method according to claim 9, comprising a step of

stimulating the T cells with an antigen.

12. (Withdrawn) The method according to claim 11, wherein the antigen is an alloantigen.

13. (Withdrawn) The method according to claim 9, further comprising a step of stimulating T cells with anti-CD3 antibody and anti-CD28 antibody.

14. (Currently amended) ~~A non-immortalized~~ An activated CD8<sup>+</sup> T cell transduced with a foreign gene prepared by the method according to claim 1.

15. (Currently amended) The method according to claim 1, wherein the contact is done with co-existence of naive CD8<sup>+</sup> T cells and activated CD8<sup>+</sup> T cells, thereby transducing a gene into activated CD8<sup>+</sup> T cells with higher efficiency than naive CD8<sup>+</sup> T cells.

16. (Canceled)

17. (Currently amended) A method of enhancing paramyxovirus vector-mediated gene transduction efficiency in ~~non-immortalized~~ CD8<sup>+</sup> T cells, wherein the method

comprises the step of activating ~~non-immortalized~~ CD8<sup>+</sup> T cells before contacting the paramyxovirus vector.

18. (Canceled)

19. (Previously presented) The method according to claim 17, wherein the T cells are antigen-activated.

20. (Withdrawn) The method according to claim 19, wherein the antigen is an alloantigen.

21. (Withdrawn) The method according to claim 19, further comprising a step of stimulating T cells with anti-CD3 antibody and anti-CD28 antibody.